Geron Corp GERN:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 03/05/21 EST
1.78quote price arrow down-0.02 (-1.11%)
Volume
28,535
Close
1.80quote price arrow up+0.03 (+1.69%)
Volume
5,059,426
52 week range
0.75 - 2.40

...

Loading . . .

KEY STATS

  • Open1.76
  • Day High1.81
  • Day Low1.68
  • Prev Close1.77
  • 52 Week High2.40
  • 52 Week High Date05/18/20
  • 52 Week Low0.75
  • 52 Week Low Date03/16/20
  • Market Cap558.85M
  • Shares Out310.47M
  • 10 Day Average Volume4.35M
  • Dividend-
  • Dividend Yield-
  • Beta1.21
  • 1 Year % Change76.47

RATIOS/PROFITABILITY

  • EPS (TTM)-0.35
  • P/E (TTM)-5.09
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-83.517M
  • ROE (MRQ)-42.00%
  • Revenue (MRQ)370,000.00
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-21,631.02%
  • Debt To Equity (MRQ)10.26%

EVENTS

  • Earnings Date03/11/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Geron Corp News

There is no recent news for this security.

Latest GERN News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Geron Corporation (Geron) is a late-stage clinical biopharmaceutical company, which is focused on development and commercialization of imetelstat, a therapeutic for hematologic myeloid malignancies. The Company operates through a single segment, which is engaged in the development therapeutic products for oncology. Imetelstat is a lipid conjugated 13-mer oligonucleotide that is designed to be complementary to and bind with high affinity to the ribonucleic acid (RNA) template...
John Scarlett M.D.
Chairman
Andrew Grethlein Ph.D.
Chief Operating Officer
Olivia Bloom
Chief Financial Officer
Aleksandra Rizo M.D. Ph.D.
Executive Vice President
Stephen Rosenfield J.D.
Executive Vice President
Address
919 EAST HILLSDALE BOULEVARD, SUITE 250
Foster City, CA
94404
United States